<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357197</url>
  </required_header>
  <id_info>
    <org_study_id>P2020-157</org_study_id>
    <nct_id>NCT04357197</nct_id>
  </id_info>
  <brief_title>Closed-loop Control Mean Arterial Pressure In Intensive Care Patients</brief_title>
  <official_title>Closed-loop Control of Vasopressor Infusion in Critically Ill Patients: A Case Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this case series is to evaluate the performance of a novel closed-loop&#xD;
      (automated) vasopressor administration system that delivers norepinephrine using feedback&#xD;
      from standard hemodynamic monitor (EV1000 Monitor) from Edwards Lifesciences (IRVINE, USA) in&#xD;
      critically ill patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this protocol, the investigators will report the percentage of case time in hypotension&#xD;
      (defined as Mean arterial pressure (MAP) &lt; 72mmHg) during a two hours study protocol in&#xD;
      critically ill patients.&#xD;
&#xD;
      The target MAP will be set at 80 mmHg, and the definition of hypotension is a MAP &lt; 90% of&#xD;
      MAP target ( 80 mmHg - 10% = 72 mmHg)&#xD;
&#xD;
      The investigators want to demonstrate that the closed-loop system can prevent hypotension at&#xD;
      this specific set point.&#xD;
&#xD;
      The investigators will test the system in a short series of 10-12 critically ill patients in&#xD;
      the ICU setting during a two hours study protocol.&#xD;
&#xD;
      Participants will receive standard patient care&#xD;
&#xD;
      Fluids will be given as a baseline crystalloid administration set at 1-2 ml/kg/h&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    We did not want to start a case series as we already finished a RCT...SO this study is now&#xD;
    outdated&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 25, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single prospective single center study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of case Time in hypotension (MAP &lt;72 mmHg)</measure>
    <time_frame>During thetwo hours study protocol</time_frame>
    <description>The primary outcome will be the percentage of case time in predefined MAP target</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of case time with MAP &gt;88 mmHg with norepinephrine still running</measure>
    <time_frame>During the two hours study protocol</time_frame>
    <description>overtreatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of vasopressors received</measure>
    <time_frame>During the two hours study protocol</time_frame>
    <description>Amount of vasopressors received (norepinephrine)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Closed-loop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Closed-loop administration of norepinephrine in critically ill patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Closed-loop</intervention_name>
    <description>The system will be tested to see if it can avoid hypotension</description>
    <arm_group_label>Closed-loop</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients in the intensive care unit (awake or under sedation)&#xD;
&#xD;
          -  Requiring norepinephrine to maintain a MAP of 80 mmHg&#xD;
&#xD;
          -  Equiped with an arterial line&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects under 18 years of age&#xD;
&#xD;
          -  Subject with Atrial Fibrillation&#xD;
&#xD;
          -  Subjects who are pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Joosten, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ERASME</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>February 20, 2021</last_update_submitted>
  <last_update_submitted_qc>February 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasme University Hospital</investigator_affiliation>
    <investigator_full_name>Alexandre Joosten, MD PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

